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Abstract 
Spinocerebellar ataxia 28 (SCA28) is an extremely rare, autosomal, dominantly inherited, 
juvenile onset, slowly progressive, gait and limb ataxia with frequent eye movement 
abnormalities and cerebellar atrophy. The causative gene of SCA28 is AFG3L2, located on 
the short arm of chromosome 18. In this paper we demonstrate the neurocognitive assessment 
of 5 affected patients in the first Hungarian SCA28 family. The identified c.2011G>C 
heterozygous base pair change is a novel point mutation variation resulting in an already 
known p.Gly671Arg amino acid change. The previously described 82 SCA28 patients were 
compared with our patients and we found that the majority of clinical features, including early 
onset, slow progression, gait and limb ataxia, dysarthria and pyramidal symptoms are similar 
to the alterations characteristic of other SCA28 patients. Some ophthalmological 
manifestations, such as ptosis, ophthalmoparesis and slowing of saccades are not present in 
our patients. Since detailed psychological investigation was not performed previously in 
SCA28 patients, the following major neuropsychological functions were examined: 
phonological immediate memory, visuospatial immediate memory, working memory, 
executive functions, everyday memory functions including semantic memory, visual attention 
and speed of processing. The results of these assessments demonstrated slightly lower levels 
of performance in complex working memory, visuospatial memory, semantic memory and 
executive functions with some variation between subjects. These abnormalities may be the 
consequence of alterations in the cerebellar-prefrontal connection system. 
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Introduction 
Autosomal, dominantly-inherited spinocerebellar ataxias (SCAs) are a continuously 
expanding, clinically and genetically heterogeneous group of neurological disorders. 
Prevalence of the autosomal dominant cerebellar ataxias (ADCAs) is estimated to be 
approximately 1-5:100,000 population [1, 2]. The main neurological symptoms are gait and 
limb ataxia and dysarthria, accompanied by additional neurological signs, which are variable 
and often overlapping within the subtypes of the group. The characteristic cognitive 
abnormalities are executive dysfunction and visuospatial disability in the most common SCAs 
(SCA1, 2 and 3) [3, 4]. The genetic diversity of SCAs comprises trinucleotide repeat 
expansions (SCA1, 2, 3, 6, 7, 8, 12, 17 and dentatorubral-pallidoluysian atrophy), 
pentanucleotide repeat expansions (SCA10 and 31), hexanucleotide repeat expansions 
(SCA36) and conventional mutations (SCA5, 11, 13, 14, 15/16, 18, 19/22, 21, 23, 26, 27, 28, 
29, 34, 35, 38 and 40), whereas the responsible gene has not yet been identified in some forms 
of SCAs (SCA4, 20, 25, 30, 32 and 37) [5].  
SCA 28 was characterized in 2006 by Cagnoli et al. as a juvenile onset, slowly progressive 
gait and limb ataxia with eye movement abnormalities [6]. The causative gene, AFG3L2 
(ATPase family gene 3-like 2), containing 17 exons, was discovered in 2010 by Di Bella et 
al., and encodes the mitochondrial metalloprotease AFG3L2 [7]. The AFG3L2 protein is a 
zinc-dependent metalloprotease which contains 797 amino acids forming four different 
domains and plays an important role in the quality control of mitochondrial proteins [7-9]. 
Most of the identified AFG3L2 mutations are missense and located in exons 15 or 16 of the 
gene. All SCA28 cases were identified in the Caucasian population, except for one patient 
from Africa reported in the literature [6-8, 10-18]. There is a lack of thorough cognitive 
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characterization of SCA28 patients in the literature. Most of the studies revealed normal 
cognitive functions in SCA28, while mild cognitive impairment or decreased intelligence 
quotient is uncommon [19].  
Here we report the detailed neurological and cognitive assessment of the first Hungarian 
family identified with a novel AFG3L2 mutation producing SCA28. The purpose of the study 
was to describe a new pathogenic mutation and to perform a clinical characterization of the 
family with SCA28, especially the cognitive aspects. With regard to the extreme rarity of the 
disease, the expectation of finding a larger sample is certainly not great, so these data are 
called as a pilot study of a small group of subjects with SCA28. 
Patients and methods 
Clinical assessment 
Five affected patients from a Hungarian family were assessed with the suspicion of hereditary 
ataxia. The neurological investigation was performed by a movement disorder specialist. The 
family tree was also delineated (Figure 1). Routine laboratory examination was carried out on 
all the affected subjects, while brain MRI was performed on 4 out of 5 patients. 
Genetic testing 
Targeted gene analysis followed by clinical exome sequencing 
After obtaining written, informed consent, genomic DNA was extracted from peripheral 
blood leukocytes by standard protocol. First, the most common SCAs (SCA1, 2, 3, 6 and 7) 
were tested in 4 out of 5 patients by CAG repeat expansion analysis. 
For clinical exome sequencing a total of 60 ng of genomic DNA was used for library 
preparation and sequenced with Trusight One clinical exome kit (Illumina) on Illumina MiSeq 
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platform. The clinical exome kit covers the coding region of 4813 clinically relevant, disease-
associated genes. 
The 150 bp paired reads were aligned to the GRCh37.75 human reference genome by 
Burrows Wheel Aligner (BWA v0.7.9a) software. The variants were called by Genome 
Analysis Toolkit HaplotypeCaller (GATK v3.5) best practice; annotated by SnpEff and 
VariantStudio softwares. Variants were filtered based on severity and frequency against 
public variant databases including dbSNP, ClinVar, ExAC, EVS and an in-house clinical 
exome database of 140 unrelated Hungarian patients. 
Cognitive characterization 
Cognitive assessment was performed on all the affected patients. The following major 
neuropsychological functions were examined: phonological immediate memory, visuospatial 
immediate memory, working memory, executive functions, semantic memory, visual 
attention and speed of processing. 
First, to obtain a brief global cognitive assessment, the Addenbrooke’s cognitive examination 
(ACE) incorporating the Mini-Mental State Examination (MMSE) was performed [20]. 
Phonological immediate memory was measured with the Digit Span Task (DST) [21]. 
Visuospatial immediate memory was assessed with the Corsi Block Tapping Test (CBTT) and 
the Brief Visuospatial Memory Test – Revised (BVMT-R) [22, 23]. Working memory was 
measured with the Backward Digit Span Task (BDST) and the Listening Span Task (LST) 
[24-26]. Letter, verb, episodic and semantic fluency tests and the Wisconsin Card Sorting Test 
(WCST) were performed as well to assess executive functions [27-29]. Everyday memory 
functions, including semantic memory, were measured with subtests of the Rivermead 
Behavioural Memory Test (RBMT) [30]. Visual attention and task switching functions were 
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investigated with the Trail Making Test (TMT) [31]. The Hamilton Rating Scale for 
Depression (HRSD) was completed as well by 2 of out of 5 patients.  
 
Results 
Clinical assessment 
Five affected patients from a Hungarian family were assessed with the suspicion of hereditary 
ataxia. First, the family tree was delineated, which suggested an autosomal dominant 
inheritance pattern (Figure 1). The first symptom of the proband (Patient 1, IV-5) was 
observed at the age of 15 years as clumsiness of the limbs which exclusively occurred after 
pronounced physical stress. In the following years, he developed uncoordinated gait, speech 
disturbance and mild double vision. The first complaints of the proband's sister (Patient 2, IV-
6) occurred as writing difficulty, gait difficulty and problems with speech when she was 28 
years old. In the next generation of the family the first symptoms of all the affected subjects 
were provoked by physical activity in high school scheduled physical education lessons. 
Actually, Patients 3 (V-3) and 4 (V-1) have complaints without physical stress as well, while 
Patient 5 (V-2) does not. Neurological examination of the patients revealed cerebellar 
symptoms of varying severity with dysarthria and eye movement abnormalities, Table 1 
demonstrates the detailed neurological characterization of patients. 
Routine laboratory parameters were in the normal range, except slightly elevated serum total 
cholesterol levels in Patients 1 and 2, and minimally increased serum creatine kinase levels in 
Patients 2 and 3. The brain MRI showed mild to moderate cerebellar atrophy mainly in the 
vermis in Patients 1-4 (Figure 2). Brainstem and supratentorial structures did not demonstrate 
pathological alterations. 
Genetic testing 
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According to autosomal dominant inheritance, the most common SCAs were investigated first 
in Patients 1-4 by CAG repeat expansion analysis. The CAG repeat numbers of SCA1, 2, 3, 6, 
7 were in the normal range, so in the next step clinical exome sequencing was performed for 
Patient 1 (IV-5; Figure 1). Searching for possible causative variants in the 48 SCA-associated 
genes, we identified 129 variants. Out of 41 non-synonymous variants, 12 were rare (based on 
available public databases ExAc, dbSNP) from which only 3 have autosomal dominant 
inheritance. We excluded ITPR1 NM_001168272.1:c.1435G>A (rs41289628) and CACNA1A 
NM_023035.2:c.6976 6993delCAGCAGCAGCAGCAGCAGinsCAGCAGCAGCAGCAG 
as possible causative mutations as both were found among unaffected Hungarian controls 
(2/148) as well. 
Thus, we identified a heterozygous missense variant c.2011G>C p.Gly671Arg, in AFG3L2 
gene (Figure 3/a). This novel mutation was not found in either the 148 unrelated Hungarian 
controls, nor in dbSNP and ExAC databases, and was not previously described in studies 
focused on AFG3L2 mutations in SCA28 [7-8, 10-18]. The presence of this mutation was 
confirmed by targeted Sanger sequencing in Patient 1 (IV-5) and in four affected, living 
relatives (IV-6, V-1, V-2 and V-3; Figure 1 and Figure 3), but was not found in a healthy 
sister (V-4) of Patient 3 (Figure 3/a). The variant is located in exon 16 of the gene (Figure 
3/c). In this position two other pathogenic nucleotide changes were detected earlier: 
c.2011G>A p.Gly671Arg by Cagnoli et al. and c.2011G>T p.Gly671Trp by Gorman et al. [8, 
11]. The identified glycine to arginine amino acid change caused by the missense mutation is 
located within a highly conserved Peptidase M41 region of the protein AFG3L2 (Figure 3/b). 
 
Cognitive characterization 
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Supplementary Table 1 shows the results of the cognitive examination, performed on all the 
affected patients. Summarily, the patients demonstrated normal cognitive performance when 
global assessment was carried out (90-96/100 point in ACE). However, they performed 
slightly lower in certain aspects relative to their age and level of education. The affected 
cognitive functions included complex working memory (LST and BDST), visuospatial 
memory (CBTT), semantic memory (RBMT immediate recall of the story), and executive 
functions (based on their performance in letter fluency). In the eldest patient (Patient 1), the 
alteration in executive functions was also supported by the fact that he made several mistakes 
in TMT B which he completed in a remarkably longer period of time, and he made mistakes 
during the clock-drawing test as well. Patient 1 performed at a lower level in WCST for 
several aspects of the task. Patient 2 also demonstrated a mild deficit in executive functions 
based on letter fluency tests and WCST. All patients scored maximum points in language 
subtests of the ACE and the neurological examination did not reveal any pathological 
alterations in this function, therefore deeper testing of language was not performed in this 
study. 
Discussion 
Here we describe the neurocognitive assessment of the first Hungarian SCA28 family caused 
by a novel heterozygous missense mutation of the AFG3L2 gene. The identified c.2011G>C 
nucleotide change is a novel variant determining the p.Gly671Arg alteration, which is 
pathogenic [8].  
Table 2 demonstrates that the clinical phenotype of our patients is similar to that of the 82 
earlier published SCA28 patients [6-8, 10-18]. The lack of ophthalmoparesis, ptosis and 
slowing of saccades in our patients are the main differences, but these symptoms usually 
appear later in the course of the disease. In our family, only Patient 1 and 2 are older than 50 
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years, while the mean age of these ophthalmological signs of the previously reported SCA28 
patients were 65.4, 57 and 55.4 years, respectively. 
Beyond that all patients demonstrated normal cognitive performance globally, the 
psychological investigation revealed mildly lower capabilities in working memory, 
visuospatial immediate memory and semantic memory, and in executive functions. These 
abnormalities are similar to the cognitive alterations were found in SCA1 (executive 
dysfunction) and SCA2 and 3 (executive and visuospatial disabilities) [3, 4]. This may reflect 
the disturbance of the cerebellar-prefrontal connection system [33, 34] due to the presented 
cerebellar abnormalities. The cognitive deficits of our patients are similar to the most 
common SCAs and might be the part of the Cerebellar Cognitive and Affective Syndrome 
(CCAS), also known as Schmahmann’s syndrome reported by Schmahmann and Sherman in 
1998 [35]. This report described 20 patients (13 cerebellar stroke, 3 postinfectious cerebellitis, 
3 cerebellar cortical atrophy and one excision of a midline tumor) with CCAS [35]. Malm et 
al. also reported young adult patients (aged 18 to 44 years) with infratentorial infarcts having 
symptoms of the CCAS in 1998 [36]. Neau et al. described the same cognitive disturbances in 
elder patients (aged: 39-75 years) with cerebellar infarcts in 2000 [37]. Fitzpatrick et al. 
investigated patients (mean age: 53.41 years) with alcoholic cerebellar degeneration and 
delineated similar cognitive abnormalities in 2013 [38]. Schmahmann’s syndrome may occur 
in children as well, Levisohn et al. and Riva et al. both published CCAS in children following 
resection of cerebellar tumors in 2000 [39, 40]. This syndrome is supposed to derive from the 
disruption of cerebellar neural circuits linking the cerebellum to prefrontal, posterior parietal, 
superior temporal and limbic cortical areas, typically leading to deficits in executive and 
visuospatial functions, language and emotional regulation [41]. There is a varying severity of 
the symptoms in patients with the same cerebellar pathology. This variability is mainly due to 
the location of the affected part of the cerebellum, because cognitive functions are supposed 
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to be chiefly mediated by the posterior lobe and dentate nucleus, while affective modulation is 
thought to be found within the flocculonodular lobes, posterior vermis and the fastigial 
nucleus. In this context, our patients demonstrated only mild deficits in executive and 
visuospatial functions. We found no significant deficits in language functions, whereas 
emotional processing was not assessed in detail. Furthermore, it is essential to note that 
performance on the applied neuropsychological tests provided only indirect information about 
functioning of the related brain areas, because the applied tasks require the coordinated 
functioning of several interconnected pathways and networks. Although the difference in age 
of the examined subjects might introduce a greater variability to study results, but the 
presentation of a single family may conversely decrease this variability by avoiding some 
interfamiliar differences. Furthermore, normal values for the corresponding age groups are 
presented with cognitive findings, where available, thereby supporting the better comparison 
of results. 
In conclusion, the novel c.2011G>C variation that was found in this Hungarian family 
demonstrated similar symptoms to previously reported cases. Reviewing the available data 
from the scientific literature, only 9 out of 82 were described to had some kind of cognitive 
abnormality, without further specification [6-8, 10-18]. Despite some limitations, including 
low case number and the fact that neuropsychological tests are poor localizers of brain 
pathology, the cognitive investigation performed in this study revealed slight abnormalities 
which may indicate the importance of integrity of cerebellar functioning in intact prefrontal 
activity [42]. These pilot findings may enhance the setup of better genotype-phenotype 
correlations in SCA 28 and other SCAs, having future therapeutic aspects as well, keeping in 
mind a later expansion of this study, hopefully with a larger number of study population to be 
able to draw statistical conclusions as well. 
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Tables (with captions) 
Table 1. Neurological characterization of the patients 
 Patient 1 
(IV-5) 
Patient 2 
(IV-4) 
Patient 3 
(V-3) 
Patient 4 
(V-1) 
Patient 5 
(V-2) 
Age at onset (years) 15 28 14-18 14-18 14-18 
Age at examination (years) 60 59 31 31 27 
Gender Male Female Male Female Female 
Gait ataxia ++ ++ + + + 
Upper limb ataxia + + + + + 
Lower limb ataxia +++ ++ ++ + + 
Dysarthria ++ ++ + + + 
Broken up smooth pursuit P P P P P 
Gaze evoked-nystagmus on horizontal testing P P P P P 
Upbeat-nystagmus on vertical testing P P - - - 
Ophthalmoparesis - - - - - 
Ptosis - - - - - 
Slowing of saccades - - - - - 
Impaired visual acuity P P - - - 
Double vision ++ - + - - 
Dysphagia ++ + - + - 
Paresis - - - - - 
Deep tendon reflexes brisk normal normal brisk brisk 
Extensor plantar reflex - - - - - 
Hypotonia + + + ++ + 
Muscle atrophy - - - - - 
Chorea, myoclonus, dystonia - - - - - 
Rigidity - - - - - 
Resting tremor - - - - - 
Impaired vibration sense - - - - - 
Incontinence - - - - - 
SARA score [30] 14/40 10/40 7.5/40 7.5/40 4.5/40 
SARA: Scale for the assessment and rating of ataxia, +: mild, ++: moderate, +++: severe, P: 
present, -: not present. 
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Table 2. Comparison of our patients’ clinical phenotype with 82 earlier described SCA 
patients [6-8, 10-18] 
 Data on 82 previously 
reported SCA28 patients 
Our patients 
Mean age at onset (years) 
(Range) 
30.88 
(3-70) 
18.2 
(14-28) 
Male/female gender 43/39 2/3 
Gait ataxia 
Mi 33/74 3/5 
Mo 32/74 2/5 
S 9/74 0/5 
Limb ataxia 
Mi 27/54 UL: 5/5; LL: 2/5 
Mo 24/54 UL: 0/5; LL: 2/5 
S 3/54 UL: 0/5; LL: 1/5 
Dysarthria 
Mi 30/63 3/5 
Mo 25/63 2/5 
S 8/63 0/5 
Nystagmus 36/65 5/5 
Ophthalmoparesis 38/70 0/5 
Ptosis 30/58 0/5 
Slowing of saccades 12/18 0/5 
Brisk/increased tendon reflexes 47/69 3/5 
Babinski sign 14/68 0/5 
Spasticity 9/71 0/5 
Mi: mild, Mo: moderate, S: severe, UL: upper limbs, LL: lower limbs. As the available data 
are limited from the literature, the numbers of affected individuals are presented out of the 
reported patients. 
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Figures (with captions) 
Figure 1. Pedigree of the assessed family. The generations are indicated with Roman 
numbers while individuals in each generation with Arabic numbers. The deceased members 
are crossed. The patients demonstrating symptoms are in black. The proband is indicated with 
P, whereas the individuals seeking genetic testing with arrows. 
Figure 2. Brain MRIs of Patient 1 and 3. Sagittal, FLAIR-weighted (a) and axial, T2-
weighted image (b) of Patient 1 demonstrates mild cerebellar atrophy, mainly in the vermis. 
Sagittal, T2-weighted (c) and axial FLAIR-weighted picture (d) of Patient 3 indicates 
moderate cerebellar atrophy. 
Figure 3. a) DNA sequence of the AFG3L2 gene in Patient 3 (upper: showing c.2011G>C 
heterozygous mutation) and in his healthy sister (lower: normal). b) The identified 
p.Gly671Arg amino acid change is located within a highly conserved region of the protein. c) 
Upper: structure of the AFG3L2 protein. Lower: Exons and locations of the SCA28 causing 
mutations of the AFG3L2 gene. Red color: the identified mutation variation in the Hungarian 
family. 
